Andrea A. Zachary

Mismatched HL-A haplotypes with antigens HL-A1, 3, and 11 associated with excellent renal allograft function

SUMMARY In a no-exclusion study of 76 genotyped recipients of living related allografts, 51 received definitely mismatched haplotypes. Those mismatched haplotypes carrying the cross reacting antigens HL-A1,3, or 11 were associated with a significantly increased incidence of excellent functioning allografts—19—and only a single failure (P < 0.001). In those patients with a mismatched haplotype without HL-A1,3, or 11, allograft failures—13—exceeded excellent functioning allografts—11. Also evaluated were the possible roles of other donor cross reacting groups, donor-recipient cross reacting antigens, specific recipient antigens such as HL-A1, lymphocytotoxic, antinuclear, and anti-glomerular basement membrane antibodies (anti-GBM), the inflammatory response and delayed hypersensitivity (DH) to dinitrochlorobenzene (DNCB), preexisting DH, and the response of recipient lymphocytes to phytohemagglutinin.

Autolymphocytotoxins in Cardiac Transplantation: Serology, Significance, and Association with HLA-A1 and HLA-A3

The presence of an autolymphocytotoxin (ALCT) in any potential organ recipient, and particularly cardiac recipients who often receive procainamide, can easily be confused with human leukocyte antigen (HLA) antibodies when serum screening and donor cross matching are done unless autocross matching and appropriate absorptions are performed. This has been a routine procedure in our pretransplant serum testing for cardiac transplant candidates and has revealed five patients with an ALCT.